PL1830835T3 - Zastosowanie agonisty receptorów waniloidowych razem z glikozaminoglikanem albo proteoglikanem do wytwarzania środka do leczenia bólów stawów i sposób stosowania tego środka - Google Patents

Zastosowanie agonisty receptorów waniloidowych razem z glikozaminoglikanem albo proteoglikanem do wytwarzania środka do leczenia bólów stawów i sposób stosowania tego środka

Info

Publication number
PL1830835T3
PL1830835T3 PL04802397T PL04802397T PL1830835T3 PL 1830835 T3 PL1830835 T3 PL 1830835T3 PL 04802397 T PL04802397 T PL 04802397T PL 04802397 T PL04802397 T PL 04802397T PL 1830835 T3 PL1830835 T3 PL 1830835T3
Authority
PL
Poland
Prior art keywords
agent
glycosaminoglycan
producing
receptor agonist
proteoglycan
Prior art date
Application number
PL04802397T
Other languages
English (en)
Inventor
Dominik Meyer
Original Assignee
Mestex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mestex Ag filed Critical Mestex Ag
Publication of PL1830835T3 publication Critical patent/PL1830835T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL04802397T 2004-12-28 2004-12-28 Zastosowanie agonisty receptorów waniloidowych razem z glikozaminoglikanem albo proteoglikanem do wytwarzania środka do leczenia bólów stawów i sposób stosowania tego środka PL1830835T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CH2004/000757 WO2006069452A1 (de) 2004-12-28 2004-12-28 Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
EP04802397A EP1830835B1 (de) 2004-12-28 2004-12-28 Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels

Publications (1)

Publication Number Publication Date
PL1830835T3 true PL1830835T3 (pl) 2012-08-31

Family

ID=34959550

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04802397T PL1830835T3 (pl) 2004-12-28 2004-12-28 Zastosowanie agonisty receptorów waniloidowych razem z glikozaminoglikanem albo proteoglikanem do wytwarzania środka do leczenia bólów stawów i sposób stosowania tego środka

Country Status (11)

Country Link
US (1) US8703741B2 (pl)
EP (1) EP1830835B1 (pl)
JP (1) JP5080983B2 (pl)
AT (1) ATE549018T1 (pl)
CA (1) CA2594203C (pl)
DK (1) DK1830835T3 (pl)
ES (1) ES2384244T3 (pl)
PL (1) PL1830835T3 (pl)
PT (1) PT1830835E (pl)
SI (1) SI1830835T1 (pl)
WO (1) WO2006069452A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2014075084A2 (en) 2012-11-12 2014-05-15 Api Genesis Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
CA2900710C (en) 2013-02-08 2023-08-08 General Mills, Inc. Reduced sodium food products
EP2818162A1 (en) * 2013-06-28 2014-12-31 Encubator AB A composition for use in the treatment of intervertebral disc-related pain
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
CA2945818C (en) * 2014-04-15 2022-05-03 Vizuri Health Sciences Llc Topical compositions comprising a capsaicinoid for pain relief, manufacture and use
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
ES3018268T3 (en) 2017-07-20 2025-05-14 Centrexion Therapeutics Corp Compositions and their use for treatment of pain using capsaicin
MX2020002692A (es) * 2017-09-11 2020-10-14 Sorrento Therapeutics Inc Formulacion de resiniferatoxina.
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2025214431A1 (zh) * 2024-04-11 2025-10-16 泰励生物科技（上海）有限公司 负载辣椒素的透明质酸交联物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
ATE481970T1 (de) * 1997-03-13 2010-10-15 James N Campbell Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
AU2000280045A1 (en) * 2000-01-24 2003-12-12 Omni Nutraceuticals, Inc. Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
US6689399B1 (en) * 2000-03-16 2004-02-10 James R. Dickson Transdermal delivery of an anti-inflammatory composition
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
US20040161481A1 (en) * 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
US20040254142A1 (en) * 2003-06-12 2004-12-16 Robert Kovler Arthritic and joint condition formulation
US20050232980A1 (en) * 2004-04-15 2005-10-20 Chen Andrew L Transdermal chondroitin and glucosamine delivery system and method of use
EP1830836B1 (de) 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels

Also Published As

Publication number Publication date
JP2008525505A (ja) 2008-07-17
EP1830835B1 (de) 2012-03-14
EP1830835A1 (de) 2007-09-12
US20080153780A1 (en) 2008-06-26
ATE549018T1 (de) 2012-03-15
JP5080983B2 (ja) 2012-11-21
US8703741B2 (en) 2014-04-22
DK1830835T3 (da) 2012-07-02
CA2594203C (en) 2014-04-29
WO2006069452A1 (de) 2006-07-06
CA2594203A1 (en) 2006-07-06
PT1830835E (pt) 2012-06-25
SI1830835T1 (sl) 2012-07-31
ES2384244T3 (es) 2012-07-02

Similar Documents

Publication Publication Date Title
PL1830835T3 (pl) Zastosowanie agonisty receptorów waniloidowych razem z glikozaminoglikanem albo proteoglikanem do wytwarzania środka do leczenia bólów stawów i sposób stosowania tego środka
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
EP1991315A4 (en) APPLICATOR FOR THE TREATMENT OF THE SKIN AND THIS USE METHOD FOR THE TREATMENT OF THE SKIN
GB2455695B (en) Apparatus and method for the reduction of pain using vibration, cold and distractive elements
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
PL373568A1 (pl) Zastosowanie inhibitorów kinazy I kappa B w leczeniu bólu
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
MX2009011744A (es) Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.
AU2003273497A8 (en) Composition of crosslinkable elastomer silicone oils for treatment by impregnation of fibrous materials
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
TW200631584A (en) A medicament related to mirtazapine for the treatment of hot flush
MX2009010757A (es) Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.
IL202001A0 (en) Axomadol for treating pain from arthritis
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
MX2007007206A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
TW200730150A (en) Methods for determining coating thickness of a prosthesis
TW200603802A (en) Method of treating neuropathic pain
UA6623U (en) Method for increasing therapeutic efficacy of clays
UA29577U (ru) Применение соединений титана для покрытия деталей корпусов медицинской физиотерапевтической аппаратуры
TW200733948A (en) Massage method and apparatus
UA4363U (uk) Спосіб лікування гострого панкреатиту
HK1139834A (en) Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists